{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:09:16Z","timestamp":1791871756263,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["IN-1150438"],"award-info":[{"award-number":["IN-1150438"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13014-018-1088-9","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T07:28:46Z","timestamp":1533194926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Sati","family":"Akbaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Henrik","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Arians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Bostel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hauswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"1","key":"1088_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09286580600977281","volume":"14","author":"JM Burr","year":"2007","unstructured":"Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol. 2007;14(1):3\u20138.","journal-title":"Ophthalmic Epidemiol"},{"issue":"4","key":"1088_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0039-6257(88)90173-7","volume":"32","author":"KM Egan","year":"1988","unstructured":"Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239\u201351.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"1088_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/107327480401100504","volume":"11","author":"CE Margo","year":"2004","unstructured":"Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer Control. 2004;11(5):304\u20139.","journal-title":"Cancer Control"},{"issue":"7","key":"1088_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archopht.119.7.969","volume":"119","author":"M Diener-West","year":"2001","unstructured":"Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119(7):969\u201382.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1088_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/archopht.119.7.951","volume":"119","author":"M Diener-West","year":"2001","unstructured":"Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS report no. 17. Arch Ophthalmol. 2001;119(7):951\u201365.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1088_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.04.035","volume":"81","author":"R Dunavoelgyi","year":"2011","unstructured":"Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M, Georg D, Zehetmayer M, Poetter R. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys. 2011;81(1):199\u2013205.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1088_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000328259","volume":"49","author":"M Zehetmayer","year":"2012","unstructured":"Zehetmayer M. Stereotactic photon beam irradiation of uveal melanoma. Dev Ophthalmol. 2012;49:58\u201365.","journal-title":"Dev Ophthalmol"},{"issue":"8","key":"1088_CR8","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.clon.2016.01.034","volume":"28","author":"V Verma","year":"2016","unstructured":"Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol). 2016;28(8):e17\u201327.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"1088_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-620X.116652","volume":"6","author":"PL Mellen","year":"2013","unstructured":"Mellen PL, Morton SJ, Shields CL. American joint committee on cancer staging of uveal melanoma. Oman J Ophthalmol. 2013;6(2):116\u20138.","journal-title":"Oman J Ophthalmol"},{"issue":"1","key":"1088_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijrobp.2012.08.026","volume":"86","author":"Z Wang","year":"2013","unstructured":"Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, Murad MH. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86(1):18\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1088_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijrobp.2015.01.029","volume":"92","author":"KK Mishra","year":"2015","unstructured":"Mishra KK, Quivey JM, Daftari IK, Weinberg V, Cole TB, Patel K, Castro JR, Phillips TL, Char DH. Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus Iodine-125 plaque therapy for choroidal and ciliary body melanoma. Int J Radiat Oncol Biol Phys. 2015;92(2):376\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1088_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijrobp.2017.02.017","volume":"98","author":"G Yazici","year":"2017","unstructured":"Yazici G, Kiratli H, Ozyigit G, Sari SY, Cengiz M, Tarlan B, Mocan BO, Zorlu F. Stereotactic radiosurgery and fractionated stereotactic radiation therapy for the treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 2017;98(1):152\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1088_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0167-8140(02)00345-6","volume":"67","author":"K Dieckmann","year":"2003","unstructured":"Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Potter R. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol. 2003;67(2):199\u2013206.","journal-title":"Radiother Oncol"},{"issue":"Suppl","key":"1088_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3171\/2012.8.GKS121002","volume":"117","author":"DW Kang","year":"2012","unstructured":"Kang DW, Lee SC, Park YG, Chang JH. Long-term results of gamma knife surgery for uveal melanomas. J Neurosurg. 2012;117(Suppl):108\u201314.","journal-title":"J Neurosurg"},{"issue":"1","key":"1088_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bjo.2008.142208","volume":"93","author":"G Modorati","year":"2009","unstructured":"Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P. Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol. 2009;93(1):40\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"2\u20133","key":"1088_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000098525","volume":"85","author":"AJ Fakiris","year":"2007","unstructured":"Fakiris AJ, Lo SS, Henderson MA, Witt TC, Worth RM, Danis RP, Des Rosiers PM, Timmerman RD. Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg. 2007;85(2\u20133):106\u201312.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"5","key":"1088_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ophtha.2004.11.038","volume":"112","author":"L Bergman","year":"2005","unstructured":"Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834\u201340.","journal-title":"Ophthalmology"},{"issue":"3","key":"1088_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/02841860500468950","volume":"45","author":"P Isager","year":"2006","unstructured":"Isager P, Ehlers N, Urbak SF, Overgaard J. Visual outcome, local tumour control, and eye preservation after 106Ru\/Rh brachytherapy for choroidal melanoma. Acta Oncol. 2006;45(3):285\u201393.","journal-title":"Acta Oncol"},{"issue":"7","key":"1088_CR19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/archopht.120.7.933","volume":"120","author":"CL Shields","year":"2002","unstructured":"Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120(7):933\u201340.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1088_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.radonc.2010.03.023","volume":"95","author":"KM Verschueren","year":"2010","unstructured":"Verschueren KM, Creutzberg CL, Schalij-Delfos NE, Ketelaars M, Klijsen FL, Haeseker BI, Ligtenberg SM, Keunen JE, Marijnen CA. Long-term outcomes of eye-conserving treatment with ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol. 2010;95(3):332\u20138.","journal-title":"Radiother Oncol"},{"key":"1088_CR21","first-page":"49","volume":"3","author":"S Aziz","year":"2009","unstructured":"Aziz S, Taylor A, McConnachie A, Kacperek A, Kemp E. Proton beam radiotherapy in the management of uveal melanoma: clinical experience in Scotland. Clin Ophthalmol. 2009;3:49\u201355.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1088_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0360-3016(00)01430-9","volume":"49","author":"M Fuss","year":"2001","unstructured":"Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys. 2001;49(4):1053\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1088_CR23","first-page":"43","volume":"100","author":"ES Gragoudas","year":"2002","unstructured":"Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal\/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002;100:43\u20138. discussion 48-49","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"1088_CR24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/bjo.2010.195594","volume":"95","author":"EC Macdonald","year":"2011","unstructured":"Macdonald EC, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uveal melanoma in Scotland. Br J Ophthalmol. 2011;95(12):1691\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1088_CR25","first-page":"28","volume":"35","author":"A Furdova","year":"2014","unstructured":"Furdova A, Sramka M, Chorvath M, Kralik G, Krasnik V, Krcova I, Waczulikova I. Stereotactic radiosurgery in intraocular malignant melanoma--retrospective study. Neuro Endocrinol Lett. 2014;35(1):28\u201336.","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"1088_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ohc.2004.08.002","volume":"18","author":"ES Gragoudas","year":"2005","unstructured":"Gragoudas ES, Marie Lane A. Uveal melanoma: proton beam irradiation. Ophthalmol Clin N Am. 2005;18(1):111\u20138. ix","journal-title":"Ophthalmol Clin N Am"},{"key":"1088_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajo.2016.02.027","volume":"165","author":"E Bensoussan","year":"2016","unstructured":"Bensoussan E, Thariat J, Maschi C, Delas J, Schouver ED, Herault J, Baillif S, Caujolle JP. Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol. 2016;165:78\u201387.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1088_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/aos.12731","volume":"93","author":"T van den Bosch","year":"2015","unstructured":"van den Bosch T, Vaarwater J, Verdijk R, Muller K, Kilic E, Paridaens D, de Klein A, Naus N. Risk factors associated with secondary enucleation after fractionated stereotactic radiotherapy in uveal melanoma. Acta Ophthalmol. 2015;93(6):555\u201360.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"1088_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0167-8140(00)00164-X","volume":"55","author":"M Zehetmayer","year":"2000","unstructured":"Zehetmayer M, Kitz K, Menapace R, Ertl A, Heinzl H, Ruhswurm I, Georgopoulos M, Dieckmann K, Potter R. Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol. 2000;55(2):135\u201344.","journal-title":"Radiother Oncol"},{"issue":"12","key":"1088_CR30","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","volume":"109","author":"LM Jampol","year":"2002","unstructured":"Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197\u2013206.","journal-title":"Ophthalmology"},{"issue":"1","key":"1088_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijrobp.2005.01.058","volume":"63","author":"K Muller","year":"2005","unstructured":"Muller K, Nowak PJ, de Pan C, Marijnissen JP, Paridaens DA, Levendag P, Luyten GP. Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2005;63(1):116\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1088_CR32","first-page":"691","volume":"96","author":"ES Gragoudas","year":"1998","unstructured":"Gragoudas ES. A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma. Trans Am Ophthalmol Soc. 1998;96:691\u2013720.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"1088_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijrobp.2003.10.007","volume":"59","author":"K Emara","year":"2004","unstructured":"Emara K, Weisbrod DJ, Sahgal A, McGowan H, Jaywant S, Michaels H, Payne D, Pintilie M, Laperriere NJ, Simpson ER. Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: preliminary results. Int J Radiat Oncol Biol Phys. 2004;59(1):94\u2013100.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1088-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-018-1088-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-1088-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T08:41:59Z","timestamp":1569314519000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-1088-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1186\/s13014-018-1088-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"9 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The final protocol was approved by the ethics committee of the University of Heidelberg, Heidelberg, Germany (S-038\/2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"140"}}